Special Investigation (Follow-up Survey of the Study of Adalimumab (D2E7) for Prevention of Joint Destruction in Patients With Rheumatoid Arthritis in Japan (M06-859(NCT00870467))

• Evaluation of adverse event [ Time Frame: at week 52 ] [ Designated as safety issue: Yes ]
  Occurrence of adverse event (yes or no), nature of adverse events, date of onset, seriousness,clinical course of adverse events, outcome, measures, causal relationship between the event and Humira
• Improvement rating on the basis of Disease Activity Score28 [ Time Frame: at week 26 ] [ Designated as safety issue: No ]
• Improvement rating on the basis of Disease Activity Score28 [ Time Frame: at week 52 ] [ Designated as safety issue: No ]
• Matrix metalloprotease-3 [ Time Frame: at week 26 ] [ Designated as safety issue: No ]
• Matrix metalloprotease-3 [ Time Frame: at week 52 ] [ Designated as safety issue: No ]
• X-ray findings for hands and feet [ Time Frame: at week 52 ] [ Designated as safety issue: No ]
• Health Assessment Questionnaire [ Time Frame: at week 26 ] [ Designated as safety issue: No ]
• Health Assessment Questionnaire [ Time Frame: at week 52 ] [ Designated as safety issue: No ]

The present survey will be conducted to evaluate the effectiveness and safety of treatment with adalimumab during the 52-week period following completion of the treatment period in the M06-859 study in patients who have continued treatment with adalimumab for 52 weeks.

The participants will be patients who have continued treatment with adalimumab until the end of the treatment period in the M06-859 study.

• Humira
  Those with an exposure
• Control (Non-Humira)
  Patients who discontinue adalimumab treatment after completion of the M06-859 study

Inclusion Criteria:

• The participants will be patients who have continued treatment with adalimumab until the end of the treatment period in the M06-859 study.

Exclusion Criteria:

• Contraindications according to the Package Insert (Patients who have serious infections, Patients who have tuberculosis, Patients with a history of hypersensitivity to any ingredient of Humira, Patients who have demyelinating disease or with a history of demyelinating disease, Patients who have cardiac failure congestive).
• Patients who use biological agents other than adalimumab after the period of treatment in the M06-859 study will be excluded from the present follow-up study.